Immuron Receives AUD $358,280 R&D Tax Concession Refund
24 November 2020 - 10:00PM
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the treatment of gut mediated diseases,
is pleased to announce that under the Australian Government’s
Research and Development Income Tax Concession incentive program,
the Company has received a cash refund of AUD $358,280 for eligible
research and development expenditure incurred during the 2020
Financial Year.
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Jerry Kanellos, Ph.D.Chief
Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a novel and safe
technology platform with one commercial asset generating revenue.
In Australia, Travelan® is a listed medicine on the Australian
Register of Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travellers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licenced natural health product (NPN 80046016) and
is indicated to reduce the risk of Travellers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection in accordance with section 403 (r)(6) of the Federal
Drug Administration (FDA).
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From May 2023 to May 2024